Nivolumab for the Treatment of Advanced Pediatric Malignancies
| Autor: | Wojciech MŁynarski, Walentyna Balwierz, Katarzyna PawiŃska-WĄsikowska, Anna Raciborska, Agata MarjaŃska, Mariusz Wysocki, Katarzyna Bobeff, BoŻenna Dembowska-BagiŃska, Agnieszka Mizia-Malarz, Monika Drogosiewicz, Jan StyczyŃski |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Combination therapy Adolescent medicine.medical_treatment Brain tumor Ipilimumab 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Internal medicine Neoplasms Medicine Humans Child business.industry Soft tissue sarcoma Melanoma General Medicine Immunotherapy medicine.disease Pediatric cancer Survival Analysis Nivolumab 030220 oncology & carcinogenesis Child Preschool Female business medicine.drug |
| Zdroj: | Anticancer research. 40(12) |
| ISSN: | 1791-7530 |
| Popis: | Background/aim Nivolumab is an immune checkpoint inhibitor with high antitumor activity in selected neoplasms. The aim of the study was to evaluate the efficacy and safety of nivolumab in pediatric patients with various types of highly malignant advanced tumors. Patients and methods Ten patients with a median age of 15.1 years were included in the study. The indications for treatment were: malignant skin melanoma (n=5), brain tumor (n=2), malignant melanoma of the brain (n=1), Hodgkin lymphoma (n=1) and soft tissue sarcoma (n=1). Results Complete disease remission was observed in 4 patients. Overall survival at 24 months from diagnosis for the entire group was 0.36. Two patients receiving combination therapy of nivolumab and ipilimumab did not achieve a remission. Adverse events of immunotherapy were observed in 4/10 patients. Conclusion Nivolumab is a promising option in pediatric advanced malignancies. Treatment with immunotherapy was relatively well tolerated, and emerging side-effects were manageable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|